Dyne Therapeutics, Inc. short interest in 2022
In 2022, Dyne Therapeutics, Inc.'s disclosed short interest ran from 5.28% of shares outstanding on 14 Jan 2022 to 4.69% on 30 Dec 2022, a change of -0.59 percentage points. The year's high was 7.39% on 30 Jun 2022 and its low 1.97% on 15 Aug 2022, averaging 4.21% across 22 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 20.32 days on 15 Jun 2022. Full history: Dyne Therapeutics, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2022 in figures
- Start of year
- 5.28% (14 Jan 2022)
- End of year
- 4.69% (30 Dec 2022)
- Change
- -0.59 pp
- High
- 7.39% (30 Jun 2022)
- Low
- 1.97% (15 Aug 2022)
- Average
- 4.21%
- Highest days to cover
- 20.32 (15 Jun 2022)
- SEC filings marked
- 8
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 5.28% | 14.90 | |
| 31 Jan 2022 | 4.21% | 3.75 | |
| 15 Feb 2022 | 4.44% | 12.89 | |
| 28 Feb 2022 | 4.58% | 12.13 | |
| 15 Mar 2022 | 3.26% | 9.89 | 10-K filed, results (8-K) |
| 31 Mar 2022 | 3.17% | 9.03 | |
| 14 Apr 2022 | 3.20% | 16.57 | |
| 29 Apr 2022 | 3.23% | 10.88 | |
| 13 May 2022 | 3.15% | 11.57 | 10-Q filed, results (8-K) |
| 31 May 2022 | 3.06% | 11.22 | |
| 15 Jun 2022 | 7.31% | 20.32 | |
| 30 Jun 2022 | 7.39% | 15.82 | |
| 15 Aug 2022 | 1.97% | 3.91 | 10-Q filed, results (8-K) |
| 31 Aug 2022 | 2.33% | 5.85 | |
| 15 Sep 2022 | 2.45% | 3.29 | |
| 30 Sep 2022 | 3.40% | 4.82 | |
| 14 Oct 2022 | 4.35% | 12.82 | |
| 31 Oct 2022 | 5.33% | 11.44 | |
| 15 Nov 2022 | 5.46% | 15.89 | 10-Q filed, results (8-K) |
| 30 Nov 2022 | 5.18% | 13.69 | |
| 15 Dec 2022 | 5.29% | 4.46 | |
| 30 Dec 2022 | 4.69% | 10.94 |
See also: Dyne Therapeutics, Inc.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.